RCKT

1.9507.58%
JS

Jonathan Schwartz

Chief Science & Gene Therapy Officer

Dr. Jonathan Schwartz, M.D., joined Rocket Pharmaceuticals, Inc. as Chief Medical Officer in January 2018 in connection with the Reverse Merger and is its Chief Science Officer since September 2025 and is its Chief Gene Therapy Officer from April 4, 2023 and served as its Chief Medical Officer since March 2024 until September 2025 and had been its Chief Medical Officer since January 2018 until April 4, 2023 and has been its Senior Vice President of Development since May 2019. Dr. Schwartz joined Private Rocket in January 2016 and served as Chief Medical Officer and Head of Clinical Development. He is responsible for leading Rocket Pharmaceuticals, Inc medical and program development. Dr. Schwartz has combined clinical practice and drug development experience. Prior to Private Rocket, Dr. Schwartz was Vice-President of Clinical Development at Stemline Therapeutics, where he oversaw development efforts for anticancer, vaccine and small-molecule platforms, a position he held since 2014. Prior to Stemline, he spent countless years at Eli Lilly and Company in several leadership positions, including Vice-President of Clinical Science, where he led development teams for numerous drug programs including ramucirumab. Previously, Dr. Schwartz was Associate Professor of Medicine at the Mount Sinai Medical Center in New York, specializing in the treatment and translational research of hepatobiliary malignancies and also served as Director for the Hematology-Oncology Fellowship training program. He has a BA in American Civilization from Brown University and an MD from Washington University (St. Louis). Dr. Schwartz completed post-graduate Internal Medicine and Hematology-Oncology training at the Mount Sinai and New York Presbyterian Hospitals.

Positions